Harry H Yoon1, Qian Shi2, Steven R Alberts2, Richard M Goldberg2, Stephen N Thibodeau2, Daniel J Sargent2, Frank A Sinicrope1. 1. Mayo Clinic, Rochester, MN (HHY, SRA, SNT, FAS); Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN (QS, DJS); Division of Medical Oncology, The Ohio State University, Columbus, OH (RMG). yoon.harry@mayo.edu sinicrope.frank@mayo.edu. 2. Mayo Clinic, Rochester, MN (HHY, SRA, SNT, FAS); Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN (QS, DJS); Division of Medical Oncology, The Ohio State University, Columbus, OH (RMG).
Abstract
BACKGROUND: It is unknown if, after controlling for clinicopathologic variables and treatment, racial disparities in colon cancer outcomes persist. Molecular marker analysis in North American patients comparing Asians with other races has not been reported. METHODS: BRAF (V600E) and KRAS mutations were analyzed in node-positive colon cancer patients (n = 3305) treated with FOLFOX-based chemotherapy in an adjuvant trial (Alliance N0147). Race categories included Asian, black, or white. Cox models were used to estimate disease-free survival (DFS) and time to recurrence (TTR). All statistical tests were two-sided. RESULTS: BRAF mutation frequency in tumors from whites (13.9%) was twice that of tumors from Asians or blacks. KRAS mutation rates were highest in tumors from blacks (44.1%). KRAS/BRAF wild-type tumors were most common among Asians (66.7%) (P overall < .001). The prognostic impact of race differed by age and N stage (both P interaction < .02). Compared with whites, blacks had shorter DFS among patients younger than age 50 years (hazard ratio [HR] = 2.84, 95% confidence interval [CI] = 1.73 to 4.66) or with N1 disease (HR = 1.54, 95% CI = 1.04 to 2.29), independent of BRAF, KRAS, and other covariates. Findings were consistent using TTR as the outcome. Asians had longer DFS among N2 tumors that was partly mediated by less frequent BRAF mutation. CONCLUSIONS: Colon cancers from Asians have a lower rate of BRAF and KRAS mutations than blacks or whites. We report a novel interaction of race with age and N stage in node-positive disease, indicating that racial disparities in survival persist despite uniform stage and treatment in a phase III trial.
BACKGROUND: It is unknown if, after controlling for clinicopathologic variables and treatment, racial disparities in colon cancer outcomes persist. Molecular marker analysis in North American patients comparing Asians with other races has not been reported. METHODS:BRAF (V600E) and KRAS mutations were analyzed in node-positive colon cancerpatients (n = 3305) treated with FOLFOX-based chemotherapy in an adjuvant trial (Alliance N0147). Race categories included Asian, black, or white. Cox models were used to estimate disease-free survival (DFS) and time to recurrence (TTR). All statistical tests were two-sided. RESULTS:BRAF mutation frequency in tumors from whites (13.9%) was twice that of tumors from Asians or blacks. KRAS mutation rates were highest in tumors from blacks (44.1%). KRAS/BRAF wild-type tumors were most common among Asians (66.7%) (P overall < .001). The prognostic impact of race differed by age and N stage (both P interaction < .02). Compared with whites, blacks had shorter DFS among patients younger than age 50 years (hazard ratio [HR] = 2.84, 95% confidence interval [CI] = 1.73 to 4.66) or with N1 disease (HR = 1.54, 95% CI = 1.04 to 2.29), independent of BRAF, KRAS, and other covariates. Findings were consistent using TTR as the outcome. Asians had longer DFS among N2 tumors that was partly mediated by less frequent BRAF mutation. CONCLUSIONS:Colon cancers from Asians have a lower rate of BRAF and KRAS mutations than blacks or whites. We report a novel interaction of race with age and N stage in node-positive disease, indicating that racial disparities in survival persist despite uniform stage and treatment in a phase III trial.
Authors: J C Stephens; J A Schneider; D A Tanguay; J Choi; T Acharya; S E Stanley; R Jiang; C J Messer; A Chew; J H Han; J Duan; J L Carr; M S Lee; B Koshy; A M Kumar; G Zhang; W R Newell; A Windemuth; C Xu; T S Kalbfleisch; S L Shaner; K Arnold; V Schulz; C M Drysdale; K Nandabalan; R S Judson; G Ruano; G F Vovis Journal: Science Date: 2001-07-12 Impact factor: 47.728
Authors: Shuji Ogino; Kaori Shima; Jeffrey A Meyerhardt; Nadine J McCleary; Kimmie Ng; Donna Hollis; Leonard B Saltz; Robert J Mayer; Paul Schaefer; Renaud Whittom; Alexander Hantel; Al B Benson; Donna Spiegelman; Richard M Goldberg; Monica M Bertagnolli; Charles S Fuchs Journal: Clin Cancer Res Date: 2011-12-06 Impact factor: 12.531
Authors: A Fariña-Sarasqueta; G van Lijnschoten; E Moerland; G-J Creemers; V E P P Lemmens; H J T Rutten; A J C van den Brule Journal: Ann Oncol Date: 2010-05-25 Impact factor: 32.976
Authors: Brooke E Sylvester; Dezheng Huo; Andrey Khramtsov; Jing Zhang; Rana V Smalling; Sope Olugbile; Blase N Polite; Olufunmilayo I Olopade Journal: Clin Cancer Res Date: 2011-11-23 Impact factor: 12.531
Authors: Wade S Samowitz; Hans Albertsen; Carol Sweeney; Jennifer Herrick; Bette J Caan; Kristin E Anderson; Roger K Wolff; Martha L Slattery Journal: J Natl Cancer Inst Date: 2006-12-06 Impact factor: 13.506
Authors: Taha M Qazi; Michael J O'Brien; Francis A Farraye; Ryan W Gould; Clara A Chen; Paul C Schroy Journal: Am J Gastroenterol Date: 2014-10-28 Impact factor: 10.864
Authors: Greg Yothers; Daniel J Sargent; Norman Wolmark; Richard M Goldberg; Michael J O'Connell; Jacqueline K Benedetti; Leonard B Saltz; James J Dignam; A William Blackstock Journal: J Natl Cancer Inst Date: 2011-10-12 Impact factor: 13.506
Authors: Uma R Phatak; Lillian S Kao; Stefanos G Millas; Rebecca L Wiatrek; Tien C Ko; Curtis J Wray Journal: Ann Surg Oncol Date: 2013-06-15 Impact factor: 5.344
Authors: Kristin Wallace; Hong Li; J Grant Brazeal; David N Lewin; Shaoli Sun; Aissatou Ba; Chrystal M Paulos; Saleh Rachidi; Zihai Li; Alexander V Alekseyenko Journal: Cancer Epidemiol Date: 2020-06-07 Impact factor: 2.984
Authors: Andrea Cercek; Maria Ignez Braghiroli; Joanne F Chou; Jaclyn F Hechtman; Nancy Kemeny; Leonard Saltz; Marinela Capanu; Rona Yaeger Journal: Clin Cancer Res Date: 2017-04-26 Impact factor: 12.531
Authors: Kristin Wallace; Allan DeToma; David N Lewin; Shaoli Sun; Don Rockey; Carolyn D Britten; Jennifer D Wu; Aissatou Ba; Anthony J Alberg; Elizabeth G Hill Journal: Clin Colorectal Cancer Date: 2016-12-07 Impact factor: 4.481
Authors: Elisabeth I Heath; Filipa Lynce; Joanne Xiu; Angela Ellerbrock; Sandeep K Reddy; Elias Obeid; Stephen V Liu; Aliccia Bollig-Fischer; Duska Separovic; Ari Vanderwalde Journal: Anticancer Res Date: 2018-04 Impact factor: 2.480
Authors: Kristin Wallace; David N Lewin; Shaoli Sun; Clayton M Spiceland; Don C Rockey; Alexander V Alekseyenko; Jennifer D Wu; John A Baron; Anthony J Alberg; Elizabeth G Hill Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-05-16 Impact factor: 4.254